Technology
Health
Pharmaceutical

Aclaris Therapeutics

$5.12
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (1.79%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ACRS and other stocks, options, ETFs, and crypto commission-free!

About

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Dermatology Therapeutics and Contract Research segments. Read More The Dermatology Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

Employees
169
Headquarters
Malvern, Pennsylvania
Founded
2012
Market Cap
211.30M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
450.27K
High Today
$5.13
Low Today
$4.85
Open Price
$5.08
Volume
311.38K
52 Week High
$21.97
52 Week Low
$4.73

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2015 IPO
US

News

Yahoo FinanceMay 16

Aclaris Therapeutics, Inc. Q1 2019 Earnings Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it Image source: The Motley Fool. Aclaris Therapeutics (NASDAQ: ACRS) Q1 2019 Earnings Call May 8, 2019, 2:00 p.m. ET Scroll to continue with content Ad Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen and welcome to the first quarter 2019 Aclaris Therapeutics Inc. earnings conference call. At this time, all participants are in a listen-only mode....

45
Yahoo FinanceMay 8

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

36
Yahoo FinanceMay 8

Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments

Submitted IND for ATI-450, an oral MK2 inhibitor RHOFADE net sales of $3.7 million for the first quarter of 2019 Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., May 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced its financial results for the first quarter of 2019, and provided an update on its clinical development and commercial programs. Highlights: ...

8

Earnings

-$1.33
-$1.10
-$0.86
-$0.63
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
β€”
Actual
Expected Aug 2, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.